Search results for " BIOMARKERS"

showing 10 items of 365 documents

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

2015

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies have led to a radical change in the treatment of several tumors, including NSCLC. In the last few years, the number of molecular biomarkers has rapidly increased, and a growing interest has been recently focused on their potential prognostic and predictive value in clinical settings. Areas covered: This review describes all the molecular biomarkers with prognostic and predictive value in NSCLC, including both clinically approved biomarkers, and emerging biomarkers under investigation in clinical trials. Liquid biopsy and applications of circulating biomarkers are also described. Expert opinion: The onco…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsOncogene Proteins Fusionmedicine.medical_treatmentClinical BiochemistryNSCLCprognostic biomarkersTargeted therapytissue biopsypredictive biomarkersInternal medicineCarcinoma Non-Small-Cell LungProto-Oncogene ProteinsDrug DiscoveryBiomarkers TumorMedicineHumansBiomarker discoveryLiquid biopsypredictive biomarkerprognostic biomarkerProtein Kinase InhibitorsPredictive biomarkerPharmacologyliquid biopsybusiness.industryDrug Discovery3003 Pharmaceutical Scienceliquid biopsy; NSCLC; predictive biomarkers; prognostic biomarkers; targeted therapy; tissue biopsy; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceProtein-Tyrosine KinasesPrognosistargeted therapyMolecular biomarkersPredictive valueClinical trialErbB ReceptorsCirculating biomarkersras Proteinsbusiness
researchProduct

Liquid Biopsy in Gynecological Cancers

2017

Gynecological cancers originate in woman’s reproductive organs, including ovarian, uterine or endometrial, cervical, vulvar, and vaginal cancers. These tumors are a leading health problem for women accounting for more than 20% of new cases and cancer-related deaths worldwide. Gynecological cancers are characterized by an aggressive biological behavior with a clinical presentation often in advanced stage of disease. This chapter will focus on the potential role of the novel molecular approaches based on liquid biopsy in detecting occult disease, monitoring the progression and identifying treatment-resistance in gynecological cancer patients. The ability to detect circulating tumor DNA (ct-DN…

Oncologymedicine.medical_specialtyPathologySettore MED/06 - Oncologia Medicabusiness.industryAdvanced stageOccult diseaseDiseaseGynecological cancerMolecular biomarkersExosomect-DNA Gynecological cancers high throughput sequencing technologiesInternal medicinemedicinePersonalized medicineLiquid biopsybusiness
researchProduct

Scalable Bio Marker Combinations for Early Stroke Diagnosis: A Systematic Review

2021

Background: Acute stroke treatment is a time-critical process in which every minute counts. Laboratory biomarkers are needed to aid clinical decisions in the diagnosis. Although imaging is critical for this process, these biomarkers may provide additional information to distinguish actual stroke from its mimics and monitor patient condition and the effect of potential neuroprotective strategies. For such biomarkers to be effectively scalable to public health in any economic setting, these must be cost-effective and non-invasive. We hypothesized that blood-based combinations (panels) of proteins might be the key to this approach and explored this possibility through a systematic review.Metho…

Oncologymedicine.medical_specialtyProtein biomarkersdiagnosisserum biomarkersFibrinogenVon Willebrand factorInternal medicinemedicineRC346-429Strokebiologybusiness.industryAntithrombinMatrix metalloproteinase 9medicine.diseasestrokeSystematic reviewNeurologybiology.proteinBiomarker (medicine)biomarker panelsneuroprotectionNeurology (clinical)Neurology. Diseases of the nervous systemSystematic Reviewbusinessmedicine.drugFrontiers in Neurology
researchProduct

Early stage screening of breast cancer using electrochemical biomarker detection

2017

Recently researchers have driven their attention in the development of biosensors for breast cancer detection using different biomarkers. This review reports a systematic study of the usefulness of marker-based electrochemical biosensors in breast cancer and its early diagnosis. Also, various types of electro-analytical methods for early stage screening of breast cancer were discussed. The emphasis is placed on immune-, geno- cyto- and enzyme-biosensing strategies. In addition, the advantages offered by some nano-materials in detection of breast cancer biomarkers are illustrated with representative recent examples that highlight the scientific interest in widening the use of new materials/m…

Oncologymedicine.medical_specialtybusiness.industry010401 analytical chemistryNew materialsNanotechnology02 engineering and technology021001 nanoscience & nanotechnologymedicine.diseaseKey issues01 natural sciences0104 chemical sciencesAnalytical ChemistryTumor BiomarkersBreast cancerInternal medicineMedicineBiomarker (medicine)Electrochemical biosensorStage (cooking)0210 nano-technologybusinessSpectroscopyBiomedicineTrAC Trends in Analytical Chemistry
researchProduct

Towards early risk biomarkers: serum metabolic signature in childhood predicts cardio-metabolic risk in adulthood

2019

AbstractCardiovascular diseases have their origin in childhood. Early biomarkers identifying individuals with increased risk for disease are needed to support early detection and to optimize prevention strategies. By applying machine learning approach on high throughput NMR-based metabolomics data, we identified metabolic predictors of cardiovascular risk in circulation in a cohort of 396 females, followed from childhood (mean age 11.2 years) to early adulthood (mean age 18.1 years). The identified childhood metabolic signature included three circulating biomarkers robustly associating with increased cardiovascular risk in early adulthood (AUC = 0.641 to 0.802, all p<0.01). These associa…

Oncologymedicine.medical_specialtybusiness.industryEarly detectionCardio metabolic riskMean ageDiseaseCirculating biomarkersIncreased riskInternal medicineCohortEarly adulthoodmedicinebusiness
researchProduct

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

2020

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)

Oncologymedicine.medical_specialtydiagnosisDown-RegulationBreast NeoplasmsReal-Time Polymerase Chain ReactionArticleCatalysislcsh:ChemistryInorganic Chemistrybreast cancerBreast cancerInternal medicinemicroRNABiomarkers TumorHumansMedicineDiagnostic biomarkerCirculating MicroRNAPhysical and Theoretical Chemistryskin and connective tissue diseaseslcsh:QH301-705.5Molecular BiologyEarly Detection of CancerplasmaSpectroscopyRetrospective StudiesEarly breast cancerPlasma samplesbusiness.industryOrganic ChemistryGeneral MedicineMiddle Agedmedicine.diseaseComputer Science ApplicationsGene Expression Regulation NeoplasticMicroRNAsROC Curvelcsh:Biology (General)lcsh:QD1-999Potential biomarkersCohortbiomarkerBiomarker (medicine)FemalebusinessInternational Journal of Molecular Sciences
researchProduct

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…

2020

Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…

PD-L10301 basic medicinerenal cell carcinomaCancer Researchmedicine.medical_treatmentLymphocytelcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicineRenal cell carcinomaPD-L1PD-1microRNAmedicineEpigeneticsmiRNAmicroRNAbiologybusiness.industrysoluble immune checkpointsImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePredictive biomarker030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbiology.proteinNivolumabbusinessReprogrammingCancers
researchProduct

Immunohistochemical detection of early myocardial infarction: a systematic review

2017

The postmortem diagnosis of early myocardial infarction is a challenge for forensic pathologists because the routine histology is neither specific. Many authors have suggested the use of the immunohistochemistry to fill the gaps in the histological diagnosis of early myocardial infarction. This review aims to analyse advances of immunohistochemical detection of early cardiac damage due to ischaemia. To this purpose, we reviewed experimental studies that investigated immunohistochemical markers and their estimated timing of expression. The review was performed according to specific inclusion and exclusion criteria, and a total of 23 studies assessing the immunohistochemical markers for the d…

Pathologymedicine.medical_specialty2734Myocardial InfarctionIschemia030204 cardiovascular system & hematologyPathology and Forensic MedicineSudden cardiac death03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleHistological diagnosisEarly myocardial infarctionmedicineAnimalsHumans030216 legal & forensic medicineMyocardial infarctionEarly myocardial infarction; Immunohistochemistry; Sudden cardiac death; Systematic review; Animals; Biomarkers; Death Sudden Cardiac; Forensic Pathology; Humans; Immunohistochemistry; Myocardial Infarction; 2734Forensic PathologyPostmortem DiagnosisAnimalbusiness.industryEarly myocardial infarction Immunohistochemistry Sudden cardiac Death Systematic reviewBiomarkermedicine.diseaseImmunohistochemistrySudden cardiac deathDeath Sudden CardiacHeart failureInclusion and exclusion criteriaSystematic reviewImmunohistochemistrybusinessBiomarkersHumanInternational Journal of Legal Medicine
researchProduct

C-reactive protein and efficacy of antiplatelet therapy in (intracranial) atherosclerosis

2018

C-reactive protein (CRP) and other inflammatory biomarkers can indicate both the severity and extent of atherosclerosis, reflecting the inflammatory nature of the disease process.1 Atherogenesis begins with an inflammatory response to vascular injury with cells and mediators initiating the healing response and later inducing growth of atherosclerotic plaques. Inflammation then increases plaque instability, promoting rupture, fissuring, or erosion—the pathogenetic milieu of thrombosis in atherothrombotic ischemic strokes.

Pathologymedicine.medical_specialtyInflammationConstriction PathologicDisease030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineHumansbiologyC-reactive protein intracranial atherosclerosisbusiness.industryIschemic strokesC-reactive proteinAtherosclerosismedicine.diseaseThrombosisInflammatory biomarkersC-Reactive Proteinbiology.proteinPlatelet aggregation inhibitorNeurology (clinical)Intracranial Atherosclerosismedicine.symptombusinessPlatelet Aggregation Inhibitors030217 neurology & neurosurgeryNeurology
researchProduct